Epizyme, Inc. (NASDAQ:EPZM)’s share price traded up 7.5% during mid-day trading on Friday . The company traded as high as $17.55 and last traded at $17.20. 1,900,596 shares were traded during mid-day trading, an increase of 195% from the average session volume of 644,820 shares. The stock had previously closed at $16.00.

Several brokerages have commented on EPZM. HC Wainwright restated a “buy” rating on shares of Epizyme in a research note on Monday, August 7th. Leerink Swann restated an “outperform” rating and issued a $28.00 price target (down previously from $31.00) on shares of Epizyme in a research note on Wednesday, August 9th. Royal Bank Of Canada restated a “buy” rating and issued a $20.00 price target on shares of Epizyme in a research note on Friday. Cowen and Company restated a “buy” rating on shares of Epizyme in a research note on Wednesday, June 7th. Finally, BidaskClub upgraded shares of Epizyme from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $23.38.

The company’s 50-day moving average price is $15.11 and its 200-day moving average price is $15.17. The company’s market cap is $1.01 billion.

Epizyme (NASDAQ:EPZM) last announced its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.08. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 63.10%. The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.95 million. During the same period in the prior year, the business earned ($0.49) earnings per share. Epizyme’s quarterly revenue was up 2027.7% on a year-over-year basis. Equities research analysts expect that Epizyme, Inc. will post ($2.39) EPS for the current fiscal year.

In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $13.44, for a total transaction of $201,600.00. Following the transaction, the insider now directly owns 22,228 shares in the company, valued at $298,744.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew E. Singer sold 3,024 shares of the company’s stock in a transaction that occurred on Friday, June 30th. The stock was sold at an average price of $15.50, for a total transaction of $46,872.00. Following the transaction, the chief financial officer now owns 40,529 shares in the company, valued at $628,199.50. The disclosure for this sale can be found here. Insiders have sold 48,024 shares of company stock worth $706,722 over the last quarter. 25.20% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of EPZM. Russell Investments Group Ltd. raised its stake in shares of Epizyme by 59.6% during the first quarter. Russell Investments Group Ltd. now owns 45,343 shares of the biopharmaceutical company’s stock worth $778,000 after buying an additional 16,924 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Epizyme by 8.2% during the first quarter. Bank of New York Mellon Corp now owns 196,837 shares of the biopharmaceutical company’s stock worth $3,377,000 after buying an additional 14,978 shares during the last quarter. UBS Asset Management Americas Inc. bought a new stake in shares of Epizyme during the first quarter worth approximately $175,000. American International Group Inc. raised its stake in shares of Epizyme by 7.1% during the first quarter. American International Group Inc. now owns 24,779 shares of the biopharmaceutical company’s stock worth $425,000 after buying an additional 1,638 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Epizyme by 0.5% during the first quarter. Principal Financial Group Inc. now owns 94,173 shares of the biopharmaceutical company’s stock worth $1,615,000 after buying an additional 515 shares during the last quarter. 83.74% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/17/epizyme-inc-epzm-trading-7-5-higher.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.